MaxCyte Q4 revenue $15.7M (+26% YoY) but core down 32%; net loss $5.3M; reiterates 2024 guidance

MAXCYTE, INC.

Q4 total revenue $15.7M (+26% YoY); core business revenue $7.2M (-32%); SPL program-related $8.5M (+359%).
Full year 2023 revenue $41.3M (-7% YoY); net loss $37.9M vs. $23.6M loss in 2022.
Cash, equivalents and investments $211.2M at Dec 31, 2023; expects ~$175M at end of 2024.
23 active SPLs at year-end, 3 more signed in Jan 2024 (now 26); 16 licensed clinical programs.
2024 guidance: core revenue flat to +5% YoY; SPL program-related ~$3M; excludes CASGEVY milestones.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. reported quarter and year ended December 31, 2023 results: revenue Total revenue of $15.7 million in the fourth quarter of 2023, net income Fourth quarter 2023 net loss was $5.3 million. Guidance reaffirmed.

Period: quarter and year ended December 31, 2023
Revenue: Total revenue of $15.7 million in the fourth quarter of 2023
Net income: Fourth quarter 2023 net loss was $5.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-002986

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.